AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$8.54
Market Cap
$384.47M
52W High
$8.85
52W Low
$2.71
ADV30
1,002,937
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 34,518,000 | 19,759,000 | 11,293,000 | -550,000 | 172,692,000 | 18,738,000 | 378,542,000 |
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
| Sep 2025 | 30,235,000 | 5,997,000 | -4,863,000 | 63,914,000 | 233,891,000 | 3,458,000 | 514,759,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,527,000
Investing CF
$70,089,000
Financing CF
$32,006,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
$-92,000
EPS Diluted TTM
$0.93
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,143,539,000
Inventory
—
Receivables
$14,062,000
ST Investments
—
EBIT TTM
$119,640,000
Pretax Income TTM
$62,493,000
Interest Exp TTM
$57,147,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$132,693,000
EBITDA
$40,610,000
Free Cash Flow
$-74,785,872
Enterprise Value
$327,636,640
Total Cash
$18,738,000
Total Debt
$40,708,000
Shares Out
45,020,407
Trailing EPS
$2.99
Book Value
$-4.67
ROE
—
ROA
12.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | -271,111,000 | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | -326,380,000 | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | -160,331,000 | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | -61,278,000 | -175,373,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Max Pain — expiry 2027-01-15
max pain strike: $5.00 · spot: $8.54 · call oi: 5,038 · put oi: 1,641
Expected Move to 2027-01-15:
±$3.70
(43.33%) —
implied range
$4.84 –
$12.24
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZURA | Zura Bio Ltd | $387.15M | $4.04 | — |
| EDIT | Editas Medicine, Inc. | $396.24M | $2.58 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $371.89M | $10.60 | — |
| CCCC | C4 Therapeutics, Inc. | $366.61M | $2.98 | — |
| KYTX | Kyverna Therapeutics, Inc. | $421.15M | $6.81 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
2026-09-20 02:09 · Yahoo
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
2026-09-10 11:30 · Yahoo
Agenus to Participate in Upcoming September Investor Conferences
2026-08-31 11:30 · Yahoo
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
2026-08-28 14:07 · Yahoo
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
2026-08-26 14:05 · Yahoo
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
2026-08-16 13:07 · Yahoo
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-07 21:45 · Yahoo
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
2026-07-17 20:11 · Yahoo
Agenus stock doubles as biotech narrows Phase 3 bet
2026-07-14 14:17 · Yahoo
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
2026-07-14 10:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.